my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Daiichi Sankyo Company, Limited and Ranbaxy Laboratories Limited announced that a binding Share Purchase and Share Subscription Agreement (the "SPSSA") was entered into between Daiichi Sankyo, Ranbaxy and the Singh family, the largest and controlling shareholders of Ranbaxy (the "Sellers"). Pursuant to the Agreement, Daiichi Sankyo will acquire the entire shareholding of the Sellers in Ranbaxy and further seek to acquire the majority of the voting capital of Ranbaxy at a price of Rs737 per share with the total transaction value expected to be between US$3.4 to US$4.6 billion (currency exchange rate: US$1=Rs43). On the post-closing basis, the transaction would value Ranbaxy at US$8.5 billion.
Sun Pharma announces closure of merger deal with Ranbaxy
Sun Pharmaceutical Industries Ltd. begins the integration of Ranbaxy’s business following the successful closure of its merger. The integration, planned by Sun Pharma over many months, will focus on supporting strong growth. The merger has fortified Sun Pharma’s position as the world’s fif ... more
Cipher Pharmaceuticals Inc. announced that it has entered into a definitive development, distribution and supply agreement with Ranbaxy Pharmaceuticals Inc. ("RPI"), a wholly owned subsidiary of Ranbaxy Laboratories Limited, under which Cipher has granted RPI the exclusive right to market, ... more
Gilead Announces Generic Viriad Licensing Agreements with Eight India-Based Companies
Gilead Sciences, Inc. announced that the company has signed eight new non-exclusive license agreements with generic companies in India. These licensing agreements grant to Alkem Laboratories Ltd., Aurobindo Pharma Ltd., FDC Ltd., J.B. Chemicals & Pharmaceuticals Ltd., Matrix Laboratories Lt ... more
Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. The Company is ... more
AstraZeneca has entered into a new global development and commercialisation agreement with Daiichi Sankyo Company, Limited for DS-1062, Daiichi Sankyo’s proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) and potential new medicine for the treatment ... more
Max Planck Society grants technology for cancer therapy
Daiichi Sankyo, Max Planck Innovation, and the Lead Discovery Center have signed an agreement providing Daiichi Sankyo with the option to receive the exclusive rights to a new lead compound for the treatment of cancer to be discovered and developed at the Lead Discovery Center. This new par ... more
Daiichi Sankyo Completes Ambit’s Acquisition
Daiichi Sankyo Company, Limited and Ambit Biosciences Corporation announced the results of Daiichi Sankyo’s tender offer to purchase all of the outstanding shares of Ambit Biosciences’ common stock for $15.00 per share plus one non-transferable contingent value right per share, which will e ... more
As a company we are oriented to the most modern work and organizational opportunities and can look out on a comprehensive spectrum of services. We expect much from our employees. But we also offer much. Our motto: performance pays! more
At our production plants in Pfaffenhofen and Altkirch, France we produce medicinal products according to the highest industry standards of GMP (Good Manufactory Practice). more
